IBB ETF Analysis: Biotechnology | NASDAQ
Healthcare Equity | NASDAQ, USA | Market Cap: 11.068m USD | 12M Return: 36.4% | US4642875565 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 361M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The iShares Biotechnology ETF (IBB) is a passively managed fund that invests at least 80% of its assets in the component securities of its underlying biotechnology index. It may allocate up to 20% of its holdings to derivatives such as futures, options, and swap contracts, as well as cash and cash equivalents. The fund is classified as non-diversified, meaning it can hold concentrated positions in a limited number of issuers rather than spreading investments broadly across the market.
As an ETF in the Health sector, IBB provides exposure to publicly traded biotechnology companies, which typically focus on developing therapies, vaccines, and diagnostics derived from biological processes. Launched in 2001 and listed on NASDAQ, the fund offers investors a way to track the performance of the biotechnology industry through a single, exchange-traded vehicle.
- FDA approval decisions drive constituent stock valuations
- Drug pricing reform pressures biotech profit margins
- GLP-1 obesity drug sales surge across major holdings
As of November 11, 2026, the stock is trading at USD 217.18 with a total of 2,160,694 shares traded. Over the past week, the price has changed by +0.79%, over one month by +6.33%, over three months by +8.59% and over the past year by +36.40%.
Current recommended Stop Loss: 203.70 (which is 6.2% or 2.3 ATR below the current price).
Biotechnology has no consensus analysts rating.